{{Rsnum
|rsid=11042725
|Gene=ADM
|Chromosome=11
|position=10303778
|Orientation=plus
|GMAF=0.3765
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
|Gene_s=ADM
}}{{PharmGKB
|RSID=rs11042725
|Name_s=ADM:(-1923)C>A
|Gene_s=ADM, SBF2
|Feature=
|Evidence=PubMed ID:19636336
|Annotation=Risk or phenotype-associated allele: C. Phenotype: In a study of patients with major depressive disorder, individuals with the CC genotype had poorer response to paroxetine than those with the A variant. Study size: 111. Study population/ethnicity: Individuals with a major depressive disorder treated with paroxetine. Significance metric(s): OR = 0.075 (95% CI 0.019-0.295); p < 0.001. Type of association: PD.
|Drugs=paroxetine
|Drug Classes=
|Diseases=Depressive Disorder, Major
|Curation Level=Curated
|PharmGKB Accession ID=PA165109603
}}
{{PMID Auto
|PMID=21075100
|Title=A genetic variant in the gene encoding adrenomedullin predicts the development of dysglycemia over 6.4 years in Chinese
}}

{{PMID Auto
|PMID=21798961
|Title=Plasma adrenomedullin level is related to a single nucleotide polymorphism in the adrenomedullin gene
}}
{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs11042725
|overall_frequency_n=46
|overall_frequency_d=128
|overall_frequency=0.359375
|n_genomes=33
|n_genomes_annotated=0
|n_haplomes=40
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=23797962
|Title=Adrenomedullin Signaling Pathway Polymorphisms and Adverse Pregnancy Outcomes.
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}